PsyBio Therapeutics Corp (PSYBF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.27: the stock has moved about 73% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerPsyBio Therapeutics Corp (PSYBF) trades at $0.00001. PsyBio Therapeutics Corp. is a biotechnology company focused on developing psychedelic-inspired medicines for mental health disorders. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for PSYBF: PSYBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
PsyBio Therapeutics Corp (PSYBF) Healthcare & Pipeline Overview
PsyBio Therapeutics Corp. is a biotechnology firm specializing in the research, development, and commercialization of psychedelic-inspired medicines targeting mental health disorders, operating within the high-growth, yet nascent, psychedelic therapeutics market, and currently based in the United States.
What Is the Investment Thesis for PSYBF?
PsyBio Therapeutics Corp. presents a high-risk, high-reward investment opportunity within the emerging psychedelic medicine market. The company's focus on developing novel treatments for mental health disorders aligns with a growing need for innovative therapies. However, the company's early stage of development and reliance on future funding introduce significant uncertainty. Key value drivers include successful preclinical and clinical trial outcomes, strategic partnerships, and regulatory approvals. The company's small market capitalization and limited financial resources necessitate careful monitoring of cash burn and potential dilution. The investment thesis hinges on PsyBio's ability to navigate the complex regulatory landscape and demonstrate the efficacy and safety of its psychedelic-inspired medicines.
Based on FMP financials and quantitative analysis
PSYBF Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- A P/E ratio of -0.00 reflects the company's current lack of profitability, typical for early-stage biotechnology firms.
- Beta of 0.27 suggests the stock is significantly less volatile than the overall market.
- The company's focus on psychedelic-inspired medicines positions it in a high-growth, albeit nascent, market segment.
- Headquartered in the United States, providing access to a large pharmaceutical market and established regulatory pathways.
Who Are PSYBF's Competitors?
PSYBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ACHFF Arch Biopartners Inc. | $0.57 | -0.35% | $38.8M | — |
| CVALF Covalon Technologies Ltd. | $2.70 | -1.10% | $74.6M | — |
| HBPCF Helix BioPharma Corp. | $1.71 | +122.08% | $131M | — |
| ICCC ImmuCell Corporation | $9.75 | 0.00% | $88.2M | 77 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.55 | +1.34% | $186M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.61 | -1.75% | $202M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.68 | -3.94% | $213M | 68 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PSYBF's Key Strengths?
Focus on the emerging market of psychedelic-inspired medicines.
- Potential for breakthrough therapies for mental health disorders.
- Proprietary formulations and intellectual property.
- Experienced management team.
What Are PSYBF's Weaknesses?
Early stage of development with limited financial resources.
- High regulatory hurdles and lengthy clinical trials.
- Dependence on future funding and partnerships.
- Small number of employees.
What Are the Key Risks for PSYBF?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Negative clinical trial results for drug candidates.
- Regulatory setbacks and delays in drug approval process.
- Competition from established pharmaceutical companies.
- Dependence on future funding and partnerships.
- Negative public perception of psychedelic drugs.
What Threats Does PSYBF Face?
- Competition from established pharmaceutical companies.
- Regulatory challenges and changing regulations.
- Negative public perception of psychedelic drugs.
- Potential for adverse side effects and safety concerns.
What Are PSYBF's Competitive Advantages?
- Proprietary formulations of psychedelic-inspired medicines.
- Intellectual property protection through patents and trademarks.
- Early mover advantage in the emerging psychedelic medicine market.
What Does PSYBF Do?
PsyBio Therapeutics Corp. is a biotechnology company dedicated to the research, development, and potential commercialization of psychedelic-inspired regulated medicines. These medicines are intended for the treatment of various mental health and other disorders. Headquartered in Coconut Creek, Florida, the company is focused on addressing unmet needs in the mental health space through innovative therapeutic approaches. PsyBio's strategy involves leveraging the potential of psychedelic compounds to create novel treatments for conditions such as depression, anxiety, and PTSD. The company is in the early stages of its development, concentrating on research and preclinical studies to advance its pipeline of drug candidates. PsyBio's focus is on developing proprietary formulations and delivery methods to enhance the efficacy and safety of its psychedelic-inspired medicines. As a relatively new entrant in the biotechnology sector, PsyBio is navigating the regulatory landscape and scientific challenges associated with psychedelic drug development. The company's success will depend on its ability to secure funding, advance its research programs, and obtain regulatory approvals for its products.
What Products and Services Does PSYBF Offer?
- Researches psychedelic-inspired medicines.
- Develops regulated medicines for mental health disorders.
- Aims to commercialize its developed medicines.
- Focuses on treatments for conditions like depression and anxiety.
- Conducts preclinical and clinical studies.
- Seeks to create novel therapeutic approaches.
How Does PSYBF Make Money?
- Focuses on research and development of psychedelic-inspired medicines.
- Aims to generate revenue through commercialization of approved drugs.
- May seek partnerships or licensing agreements with larger pharmaceutical companies.
What Industry Does PSYBF Operate In?
PsyBio Therapeutics Corp. operates within the biotechnology industry, specifically targeting the emerging market for psychedelic-inspired medicines. This market is driven by increasing awareness of mental health disorders and the limitations of existing treatments. The competitive landscape includes both established pharmaceutical companies and smaller biotech firms exploring psychedelic compounds. The industry is characterized by high regulatory hurdles, lengthy clinical trials, and significant investment in research and development. The growth potential is substantial, driven by the potential for breakthrough therapies and increasing acceptance of psychedelic medicine.
Who Are PSYBF's Key Customers?
- Patients suffering from mental health disorders.
- Healthcare providers who prescribe medications.
- Pharmaceutical companies interested in licensing or acquiring new drugs.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
PsyBio Therapeutics Corp operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Denver, US. PSYBF has traded publicly since 2021.
Financial Health
PsyBio Therapeutics Corp's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Earnings Track Record
PsyBio Therapeutics Corp has missed Wall Street's EPS estimate in 3 of its last 5 reported quarters — a mixed record worth weighing. Reported results have landed about 65.7% below estimates on average.
PSYBF Financials
PSYBF Latest News
No recent news available for PSYBF.
PSYBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PSYBF.
Price Targets
Wall Street price target analysis for PSYBF.
PSYBF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PSYBF; grades run from A+ (80-100) to F (below 30).
Leadership: Evan Mike Levine
CEO
Evan Mike Levine serves as the CEO of PsyBio Therapeutics Corp. As CEO, he is responsible for leading the strategic direction of the company, overseeing research and development activities, and securing funding to advance PsyBio's pipeline of psychedelic-inspired medicines. His leadership is crucial for navigating the complex regulatory landscape and building partnerships within the biotechnology industry.
Track Record: Due to limited information, it is difficult to assess Evan Mike Levine's specific track record at PsyBio Therapeutics Corp. However, his leadership is essential for guiding the company through its early stages of development, securing funding, and advancing its research programs. Success will be measured by the company's ability to achieve key milestones, such as positive clinical trial results and regulatory approvals.
PSYBF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that PsyBio Therapeutics Corp. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies on the OTC Other tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is generally associated with higher risk due to the potential for less transparency and greater price volatility. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume on the OTC market.
- Potential for price manipulation and fraud.
- Lack of regulatory oversight and transparency.
- Higher risk of financial distress or bankruptcy.
- Limited access to capital markets.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Determine the company's capital structure and debt levels.
- Understand the company's regulatory environment and compliance requirements.
- Consult with a financial advisor or legal professional.
- Company is registered and in good standing with the relevant regulatory authorities.
- Company has a clear business plan and strategy.
- Company has a qualified management team with relevant experience.
- Company has secured funding from reputable investors.
- Company has a valid website and contact information.
Common Questions About PSYBF (Healthcare)
What do analysts say about PSYBF stock?
As of March 17, 2026, there is no readily available analyst coverage for PSYBF stock due to its OTC listing and small market capitalization. Consequently, there is no consensus rating or price target.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is limited due to the company's OTC listing and early stage of development.
- Financial data may not be readily available or up-to-date.